Topic

Blue Cross Blue Shield (BCBS Association)

A collection of 1330 issues

How to Get Kesimpta (Ofatumumab) Covered by Blue Cross Blue Shield in California: Prior Authorization, Appeals & Cost Savings

Answer Box: Getting Kesimpta Covered by Blue Shield of California Kesimpta (ofatumumab) requires prior authorization from Blue Shield of California for relapsing multiple sclerosis. The fastest path to approval: 1) Submit PA request with MS diagnosis (ICD-10: G35) and documentation of failed/contraindicated alternatives like Betaseron or Copaxone, 2) Obtain
7 min read

How to Get iLink® Corneal Cross-Linking Covered by Blue Cross Blue Shield in Texas: Complete Prior Authorization and Appeals Guide

Answer Box: Getting iLink® Covered by BCBS Texas Blue Cross Blue Shield of Texas (BCBSTX) covers iLink® corneal cross-linking for progressive keratoconus when medically necessary per their 2024 policy. Success requires: (1) documented corneal progression (≥1 diopter change over 12 months via topography), (2) prior authorization through your ophthalmologist, and
5 min read

How to Get Strimvelis Gene Therapy Covered by Blue Cross Blue Shield in Illinois: Complete Guide to International Treatment Authorization and Appeals

Answer Box: Getting Strimvelis Covered in Illinois Strimvelis gene therapy for ADA-SCID requires special authorization from Blue Cross Blue Shield of Illinois (BCBSIL) as an experimental/international treatment. Start by calling BCBSIL member services at 1-800-892-2803 to verify international coverage benefits and request experimental treatment exception forms. Submit comprehensive medical
5 min read

How to Get Onivyde (Irinotecan Liposome) Covered by Blue Cross Blue Shield in Pennsylvania: Complete Appeal Guide with Forms and Timelines

Quick Answer: Getting Onivyde Covered by Blue Cross Blue Shield in Pennsylvania Blue Cross Blue Shield plans in Pennsylvania require prior authorization for Onivyde (irinotecan liposome) as a specialty cancer treatment. Submit PA requests through your plan's provider portal with pathology-confirmed metastatic pancreatic adenocarcinoma, ECOG performance status 0-1,
6 min read